AMC Entertainment is planning to reinvest up to $1.5 billion in its theaters but faces a balancing act amid debt repayments, ...

Dan Ives, Wedbush Securities analyst, joins CNBC's 'Squawk on the Street' to discuss outlooks on Tesla following Donald Trump ...

The Trump administration could be a boon for business for private prison companies in the U.S. if the president-elect ...

Wedbush analyst Matt Bryson lowered the firm’s price target on Supermicro (SMCI) to $32 from $62 and keeps a Neutral rating on the ...

M/I Homes (MHO) was trading higher after Wedbush Securities upgraded the home builder on a better-than-expected business activity. "MHO's orders were 5% lower in July, 2% higher in August ...

With a Donald Trump win for the White House looking very likely, Wedbush expects a “very robust bullish market reaction.” The ...

Wedbush has a “Outperform” rating and a $33.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($1.65) per share.

Wedbush analyst S. Devitt now anticipates that the company will post earnings per share of $0.26 for the year, up from their prior forecast of ($0.05). Wedbush currently has a “Neutral” rating ...

Wedbush added Roblox (RBLX) to the firm’s “Best Ideas List” while keeping an Outperform rating on the shares with a $49 price ...

Wedbush Securities upgraded shares of Affirm (AFRM) and Upstart Holdings (UPST) from Underperform to Neutral; the analyst team also upped both companies' price targets to $45 per share.

Elon Musk’s massive bet on former President Trump appears to have paid off, as the billionaire owner of Tesla and SpaceX ...

Dan Ives expects Trump's victory to be a boon for Tesla stock. The Wedbush analyst explained why in an interview with CNBC ...